OR WAIT 15 SECS
ICYMI, this week we featured a new episode of The Cutaneous Connection, a hyperspectral technology company helping to investigate COVID-19-related skin findings, cannabinoid-containing products and their effects on prescription medications, plus more.
In case you missed it, this week we released a new episode of our podcast The Cutaneous Connection discussing probiotics as a possible treatment for psoriasis and other inflammatory skin diseases. We also featured articles on a hyperspectral technology company helping to investigate COVID-19-related skin findings, cannabinoid-containing products and their effects on prescription medications, the U.S. Food and Drug Administration (FDA) granting a Fast Track Designation to delgocitinib for chronic hand eczema, plus more.
This week’s edition of The Mainstream Patient features stories about sun spots, niacinamide, proper body hair removal, psoriasis-related mental health treatment, plus more.
Due to the financial fallout caused by COVID-19, many practices are struggling to keep their doors open. What options to physicians have? This expert says hope lies within value-based care.
Demandforce introduces their mobile app, which is available free to all Demandforce users and is aimed at making practice operations and the lives of physicians easier through streamlined communication and office efficiency.
The Centers for Medicare & Medicaid Services (CMS) has proposed a permanent expansion of telehealth to ensure healthcare access in rural areas.
SilcSkin introduces their Multi-Area Pads to help treat fine lines and wrinkles in the mouth area.
The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients ages 6 to 17 years in the European Union.
The American College of Physicians (ACP) claims the changes to payments for offices visits will benefit physicians and practices.
Researchers have identified and developed lists of medications that may not function properly due to concomitant cannabinoid use in an effort to help medical professionals prescribe drugs safely to their patients.
A recently published study finds from 2008 to 2017, primary care physicians received only a slightly greater rise in compensation than specialists under the 2010 Affordable Care Act.
The U.S. Food and Drug Administration (FDA) has granted JAK-inhibitor delgocitinib cream (LEO Pharma) Fast Track Designation for chronic hand eczema.
This episode dives into emerging research regarding probiotics specifically tailored to treat psoriasis and possibly other inflammatory skin diseases.
Hyperspectral imaging company HinaLea Imaging is using their technology to study the skin manifestations of patients who are critically ill with COVID-19 to help identify the prognostic value of these skin symptoms.
Researchers examined a group of adult women diagnosed with melasma who applied a traditional medicinal product on one side of their face and 4% hydroquinone on the other side.
COVID-19 has left providers with fewer in-office visits, more telehealth appointments and, for many, reduced revenue.
The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.